You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
The Medicare Administrative Contractor will provide limited coverage for the RNA gene expression test that helps rule out primary cutaneous melanoma.
Based on expression patterns in mouse strains with variable infection susceptibility, investigators came up with a signature that predicted Ebola virus response in West Africa patients.
The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.
Transcriptome profiles in ovarian cells from young and old non-human primates unearthed expression changes that coincided with flagging fertility in humans.
Exome sequences for nearly 35,600 cases and controls revealed genes prone to mutation in autism spectrum disorder, along with related cell types, functions, and developmental stages.
Blood and skin cell transcriptomes revealed a JAK-STAT signaling and human herpesvirus targets in an individual with refractory drug-induced hypersensitivity syndrome.
The researchers identified 240 metabolite-locus associations, including novel gene candidates for biotransformation and detoxification reactions.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.